Table 1.
A | B | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ID. | ORF3a | N | Nsp12 | Nsp5 | S(A) | S(B) | S-RBD | M | ID. | ORF3a | N | Nsp12 | Nsp5 | S(A) | S(B) | S-RBD | M |
dC1 | dP1 | ||||||||||||||||
dC2 | dP2 | ||||||||||||||||
dC3 | dP3 | ||||||||||||||||
dC4 | dP4 | ||||||||||||||||
dC5 | dP5 | ||||||||||||||||
dC6 | dP6 | ||||||||||||||||
dC7 | dP7 | ||||||||||||||||
dC8 | dP8 | ||||||||||||||||
dC9 | dP9 | ||||||||||||||||
dP10 | |||||||||||||||||
dP11 | |||||||||||||||||
dP12 | |||||||||||||||||
dP13 | |||||||||||||||||
dP14 | |||||||||||||||||
dP15 | |||||||||||||||||
dP16 | |||||||||||||||||
dP17 | |||||||||||||||||
dP18 |
PBMC of 9 subjects with SARS-CoV-2-PCR-verified infection (A) and PBMC from 18 subjects from the Pre-Covid Era (B) where tested in an ELISPOT assay for reactivity to the specified SARS-CoV-2 mega peptide pools. (These peptide pools are closer defined in Supplementary Table 2 ). All peptide pools were tested in 4 serial dilutions on each PBMC sample at 1.5 ug/mL, 0.5 ug/mL, 0.17 ug/mL, and 0.06ug/mL. Affinity levels are color-coded. Red: high affinity, defined as four consecutive peptide dilutions eliciting a positive recall response with SFU counts exceeding 3 SD of the negative peptide pool-based background. Orange: intermediate affinity, defined as three consecutive peptide dilutions eliciting a positive recall response. Yellow: low affinity, with only the two highest peptide concentrations eliciting positive SFU counts. Beige: only the highest concentration of peptide is positive. The raw counts are provided in Supplementary Table 5 .